US FDA extends review of Travere’s drug for rare kidney diseaseJan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’TVTX.O drug to treat a type of rare kidney disorder, the drugmaker said on Tuesday.
The agency will now give its decision on April 13, compared to its previous action date of January 13.
(Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
((Sahil.Pandey@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments